T1	Participants 385 472	31 women with FIGO stage IB2-IVA cervical cancer or with postsurgical pelvic recurrence
T2	Participants 840 873	Patient and tumor characteristics
T3	Participants 1052 1116	Seven patients (44%) of group I and 8 patients (53%) of group II
T4	Participants 967 1035	87% and 80% of patients receiving at least 4 doses in groups I and I
